Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.84 -0.3%	$4.91	$1.14 ▼ $7.20	$349.82M	0.76	1.17 million shs	453,118 shs
BNTC Benitec Biopharma	$13.24 +1.6%	$12.39	$8.06 ▼ $17.15	$347.55M	0.4	68,925 shs	45,169 shs
CTMX CytomX Therapeutics	$2.04 -0.5%	$2.25	$0.40 ▼ $3.10	$336.42M	2.13	3.26 million shs	1.21 million shs
ORMP Oramed Pharmaceuticals	$2.20	$2.14	$1.82 ▼ $3.09	$90.20M	1.6	138,650 shs	83,455 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+0.17%	-0.34%	+15.13%	+171.30%	+11.62%
BNTC Benitec Biopharma	+1.32%	+2.60%	+17.92%	-13.54%	+42.56%
CTMX CytomX Therapeutics	-0.97%	+0.99%	-8.89%	-18.65%	+76.72%
ORMP Oramed Pharmaceuticals	-0.45%	+6.80%	0.00%	-6.38%	-8.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	1.8199 of 5 stars	3.3	1.0	0.0	2.0	1.7	0.6
BNTC Benitec Biopharma	1.5529 of 5 stars	3.6	1.0	0.0	2.4	0.8	0.0
CTMX CytomX Therapeutics	4.1987 of 5 stars	3.5	1.0	4.7	2.8	1.7	1.3
ORMP Oramed Pharmaceuticals	0.853 of 5 stars	0.0	3.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	62.67% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	96.37% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	181.86% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, CTMX, ALDX, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
BNTC Benitec Biopharma	$80K	4,344.38	N/A	N/A	$4.68 per share	2.83
CTMX CytomX Therapeutics	$138.10M	2.44	$0.36 per share	5.72	$0.73 per share	2.79
ORMP Oramed Pharmaceuticals	$1.34M	67.31	N/A	N/A	$3.75 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.64	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.35	N/A	N/A	N/A	N/A	-19.37%	-18.28%	11/6/2025 (Estimated)

Latest ORMP, CTMX, ALDX, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q4 2025	BNTC Benitec Biopharma	-$0.24	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	ORMP Oramed Pharmaceuticals	-$0.04	-$0.05	-$0.01	$0.31	N/A	N/A
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
BNTC Benitec Biopharma	0.01	14.80	14.80
CTMX CytomX Therapeutics	N/A	4.20	4.20
ORMP Oramed Pharmaceuticals	N/A	26.82	26.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BNTC Benitec Biopharma	52.19%
CTMX CytomX Therapeutics	67.77%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
BNTC Benitec Biopharma	1.30%
CTMX CytomX Therapeutics	6.60%
ORMP Oramed Pharmaceuticals	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.15 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
ORMP Oramed Pharmaceuticals	10	41.00 million	33.71 million	Optionable

ORMP, CTMX, ALDX, and BNTC Headlines

Recent News About These Companies

Oramed Pharm Approves Stock Incentive Plan Amendment

August 21, 2025 | tipranks.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 18, 2025 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?

August 15, 2025 | marketbeat.com

Oramed Pharmaceuticals (ORMP) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Zacks Small Cap Has Negative Outlook for ORMP Q2 Earnings

August 1, 2025 | marketbeat.com

With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio

July 29, 2025 | msn.com

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

February 11, 2025 | contractpharma.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, CTMX, ALDX, and BNTC Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.84 -0.02 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$5.96 +0.12 (+2.12%)

As of 05:38 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Benitec Biopharma NASDAQ:BNTC

$13.24 +0.21 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$13.64 +0.40 (+3.06%)

As of 05:16 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

CytomX Therapeutics NASDAQ:CTMX

$2.04 -0.01 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.08 (+3.68%)

As of 05:49 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.20 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 -0.02 (-0.91%)

As of 05:31 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time